Description: GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
Home Page: www.glycomimetics.com
GLYC Technical Analysis
9708 Medical Center Drive
Rockville,
MD
20850
United States
Phone:
240 243 1201
Officers
| Name | Title |
|---|---|
| Mr. Harout Semerjian | CEO, Pres & Director |
| Mr. Brian M. Hahn | Sr. VP & CFO |
| Dr. John L. Magnani Ph.D. | Sr. VP of Research & Chief Scientific Officer |
| Ms. Stephanie R. Irish CPA | VP of Accounting |
| Mr. Christian Dinneen-Long | VP, Corp. Counsel & Corp. Sec. |
| Mr. Armand Girard | Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel. |
| Mr. Bruce Johnson | Sr. VP & Chief Commercial Officer |
| Dr. Edwin Rock M.D., Ph.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.4078 |
| Price-to-Sales TTM: | 1154.5992 |
| IPO Date: | 2014-01-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 52 |